Hence, by targeting PSMA, which is overexpressed in cancer cells, and FAP, which is overexpressed in tumor stroma, we hypothesized that it would potentially increase the lesion detection rate and tumor retention in prostate cancer patients. This evidence concerns the gene FOLH1 and prostate carcinoma.